Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Efficacy and safety of KRd or KCd induction in multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 714
Rating:

Dr Francesca Gay - University of Torino, Torino, Italy

Dr Francesca Gay speaks to ecancer at ASH 2018 about the Forte trial into the efficacy and safety of KRd or KCd induction in multiple myeloma.

She explains that the three arms of the study were KRd induction-ASCT-KRd consolidation vs KCd induction-ASCT-KCd consolidation vs 12 cycles of KRd.

Dr Gay reports that both the KRd transplant treatments and extended therapy significantly improved the response rate in comparison with treatment with KCd and transplant.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation